OakChart

Eupraxia Pharmaceuticals Inc

EPRXHealthcare·Biotechnology·Canada·Small·NASD·Nov 11 • 3:59 PM ET

8.06+0.43 (5.64%)
2026-11-12 00:48 CET
Market cap
513.06 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-61.48 USD m
Free cash flow, TTM
-44.53 USD m
EPS diluted, TTM
-1.03
P/E
-
Compare

Price

EPRX against its 20, 50 and 200-day averages
2050200beatmiss
6.007.008.009.001.8M3.6MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26EPRXclose 8.0620-day 7.1350-day 7.62200-day 7.248.0652w high52w low

13.5% under the 52-week high of 9.32 on 21 Jan 2026. 52-week low 5.63 on 16 Jun 2026. Last 15 sessions, 34.8% high to low

Volume 0.93× normal · the line is the 50-bar volume average

Profile

EPRX
52-week range, 66% of the way up
5.639.32

Eupraxia Pharmaceuticals, Inc. operates as a drug delivery technology company in Canada. It delivers drugs into body compartments, such as the joint without any of the common issues with body compartment injections, such as systemic exposure. The firm focuses on arthritis, diabetic macular edema, and chronic pain programs. The company was founded by James A. Helliwell, John Salvatore Montalbano and Amanda Malone on May 12, 2011 and is headquartered in Victoria, Canada.

Employees49
IPOAug 03, 2021
Beta1.23
ATR, 14d0.53
Rel volume0.93
Short float11.42%
Insider own18.62%
Inst own43.29%

Snapshot

6 groups

Valuation

Index-
Market Cap541.95M
Enterprise Value448.47M
Income-61.48M
Sales0.00M
Book/sh1.36
Cash/sh1.88
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees49
IPOAug 03, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B5.92
P/C4.29
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio12.25
Current Ratio12.25
Debt/Eq0.03
LT Debt/Eq0.02
Option/ShortNo / Yes

Earnings

EPS (ttm)-1.03
EPS next Y-1.07
EPS next Q-0.27
EPS this Y7.38%
EPS next Y-11.95%
EPS next 5Y-6.35%
EPS past 3/5Y-2.38% -34.75%
Sales past 3/5Y- -
EPS Y/Y TTM-18.46%
Sales Y/Y TTM-
EPS Q/Q-23.45%
Sales Q/Q-
EarningsNov 10 AMC
EPS/Sales Surpr.13.70% -

Ownership

Insider Own18.62%
Insider Trans0.00%
Inst Own43.29%
Inst Trans2.47%
ROA-52.06%
ROE-55.97%
ROIC-47.65%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA2013.11%
SMA505.79%
SMA20011.36%
Trades-

Technical

Shs Outstand67.24M
Shs Float54.72M
Short Float11.42%
Short Ratio9.39
Short Interest6.25M
52W High9.32 -13.52%
52W Low5.63 43.16%
Volatility7.63% 7.17%
ATR (14)0.53
RSI (14)61.06
Beta1.23
Rel Volume0.93
Avg Volume665.18K
Volume615,861

Performance

Perf Week19.23%
Perf Month20.66%
Perf Quarter20.84%
Perf Half Y6.75%
Perf YTD6.75%
Perf Year23.43%
Perf 3Y103.63%
Perf 5Y258.22%
Perf 10Y-
Recom1.00
Target Price16.10
Prev Close7.63
Price8.06
Change %5.64%

Analyst ratings

latest 10 of 10
DateActionAnalystRating changeTargetImplied
Nov 09, 2026InitiatedRRBC Capital MktsOutperform$14+73.7%
Sep 24, 2026InitiatedWWedbushOutperform$17+110.9%
Jun 26, 2026InitiatedOOppenheimerOutperform$17+110.9%
May 21, 2026InitiatedSStifelBuy$25+210.2%
Mar 23, 2026InitiatedWWilliam BlairOutperform
Jul 24, 2025InitiatedCCantor FitzgeraldOverweight$11+36.5%
Jun 26, 2025InitiatedHH.C. WainwrightBuy$12+48.9%
Jun 16, 2025InitiatedCCanaccord GenuitySpeculative Buy
Feb 21, 2025InitiatedCCraig HallumBuy$12+48.9%
Nov 14, 2024InitiatedRRodman & RenshawBuy$9+11.7%

Peers

Mkt cap
TickerCompanyMkt cap
HRTXHeron Therapeutics Inc68.36M
EYPTEyePoint Inc30.74M
PCRXPacira BioSciences Inc1.46B
OCULOcular Therapeutix Inc1.47B
PYPDPolypid Ltd134.06M
ANIKAnika Therapeutics Inc186.86M
TARSTarsus Pharmaceuticals Inc3.78B
UPBUpstream Bio Inc175.27M
CNTBConnect Biopharma Holdings Ltd43.38M
DWTXDogwood Therapeutics Inc45.11M

News

latest 14 of 166
  • Eupraxia Pharmaceuticals Establishes At-The-Market Offering Program (GlobeNewswire) +5.64%
  • Eupraxia Pharmaceuticals Reports Third Quarter 2026 Financial Results (GlobeNewswire)
  • Eupraxia Pharmaceuticals to Participate at Upcoming Conferences and Host a Virtual Analyst Day (GlobeNewswire)
  • Eupraxia Pharmaceuticals Reaches its Enrollment Target for the RESOLVE Trial Investigating EP-104GI for the Treatment of Eosinophilic Esophagitis (GlobeNewswire)
  • Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences (GlobeNewswire)
  • Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis (GlobeNewswire) +9.57%
  • Eupraxia Pharmaceuticals Completes Transfer to the Nasdaq Global Select Market and Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
  • Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients (GlobeNewswire)
  • Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results (GlobeNewswire)
  • Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth (GlobeNewswire)
  • Eupraxia Pharmaceuticals Strengthens Board with Three Industry Leaders in Drug Development and Commercialization (GlobeNewswire)
  • Eupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of Shareholders (GlobeNewswire)
  • Eupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
  • Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-10-0.226-0.262-0.2340.000.007
2026Q22026-08-11-0.222-0.225-0.2280.000.008
2026Q12026-05-12-0.207-0.193-0.2330.000.006
2025Q42026-03-13-0.291-0.152-0.3340.000.007
2025Q32025-11-04-0.190-0.179-0.1900.000.006
2025Q22025-08-12-0.242-0.187-0.2610.000.006
2025Q12025-05-06-0.190-0.175-0.2070.000.003
2024Q42025-03-20-0.210-0.155-0.2110.000.004
2024Q32024-11-07-0.121-0.130-0.1670.000.001
2026Q4---0.270--0.005
2027Q1---0.245--0.006
2027Q2---0.152--0.006
2027Q3---0.263--0.006
2027Q4---0.275--0.006
2028Q1---0.233---1
2028Q2---0.265---1

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2023FY-0.590-0.614-1.1690.000.00
2024FY-0.760-0.645-0.7520.000.00
2025FY-0.981-0.627-1.0300.000.00
2026FY--0.954--0.00
2027FY--1.068--0.50
2028FY--1.239--3.89
2029FY--1.385--20.49
2030FY--0.935--89.71

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-118000.000.000.00
2026Q4S2026-11-108000.000.000.00
2026Q4S2026-11-068000.000.000.00
2026Q4S2026-09-237000.000.000.00
2026Q4S2026-08-126000.000.000.00
2026Q4S2026-06-246000.000.000.00
2026Q4S2026-05-135000.000.000.00
2026Q4S2026-04-205000.000.000.00
2026Q4S2026-03-164000.000.000.00
2026Q4S2026-03-133000.000.000.00
2026Q4S2025-12-112000.000.000.00
2026Q4S2025-11-113000.000.000.00
2026Q4S2025-11-103000.000.000.00
2026Q4R2026-11-11310-0.28-0.35-0.23

Estimate history

EPS, annual-0.259-0.794-0.42-0.232-1.288-0.959-1.169-0.752-1.029-1.0291
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.167-0.211-0.207-0.261-0.19-0.334-0.233-0.228-0.234
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0000000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual12.86512.86512.86512.86514.24321.59327.28235.64251.93967.242
Period201720182019202020212022202320242025MRQ
Shares, quarterly35.62335.64235.84935.9650.59851.93961.80965.47467.242
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.480.240.170.160.150.090.090.150.10
Gross Profit-0.48-0.24-0.17-0.16-0.15-0.09-0.09-0.15-0.10
Selling, General and Administrative Excl. Other65.9138.2026.8327.9217.7914.641.754.859.21
Research and Development42.2821.1415.9420.6613.837.930.812.585.26
Other Operating Expense0.000.000.000.000.00-0.000.000.00
Operating Income-66.39-38.43-27.00-28.07-17.94-14.73-1.84-5.01-9.30
Interest Expense0.000.000.961.170.981.031.401.100.11
Unusual Expense0.000.00-1.200.841.063.20-0.09-0.021.88
Net Income Before Taxes-59.07-38.59-25.74-29.03-19.03-18.64-2.99-5.46-11.44
Income Taxes0.050.020.00-0.07-0.040.000.000.000.00
Consolidated Net Income-59.09-38.61-25.74-28.97-18.99-18.64-2.99-5.46-11.44
Net Income From Continuing Operations-59.07-38.58-25.50-28.22-18.49-18.34-2.98-5.41-10.21
Net Income-61.48-41.11-25.50-28.22-18.49-18.34-2.98-5.41-10.21
EPS (Recurring)-0.91-1.03-0.78-1.14-0.92-1.13-0.24-0.42-0.69
EPS (Basic, Before Extraordinaries)-1.03-1.03-0.75-1.17-0.96-1.29-0.23-0.42-0.79
EPS (Diluted)-1.03-1.03-0.75-1.17-0.96-1.29-0.23-0.42-0.79
EBITDA-65.91-38.20-26.83-27.92-17.79-14.64-1.75-4.85-9.21
Non-Operating Income (Expense)7.32-0.151.021.050.950.320.160.63-0.15
Other After Tax Adjustments0.020.000.000.000.000.000.000.000.00
Stock Option Compensation Expense10.196.442.551.121.433.360.170.412.25
Shares Outstanding67.2451.9435.6427.2821.5914.2412.8712.8712.87
Market Capitalization513.06513.06112.92113.4557.5532.7632.76--

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.180.130.090.070.060.060.050.05
Gross Profit-0.18-0.13-0.09-0.07-0.06-0.06-0.05-0.05
Selling, General and Administrative Excl. Other15.9817.9715.8716.096.828.217.087.43
Research and Development10.6712.7011.107.814.375.153.813.83
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-16.16-18.10-15.96-16.16-6.88-8.26-7.12-7.48
Interest Expense0.000.000.000.000.00--0.36
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-15.26-14.46-12.64-16.71-6.37-8.74-6.76-7.53
Income Taxes-0.010.030.010.01-0.000.010.000.00
Consolidated Net Income-15.25-14.49-12.63-16.72-6.37-8.75-6.77-7.53
Net Income From Continuing Operations-15.24-14.49-12.63-16.71-6.36-8.74-6.76-7.51
Net Income-15.83-15.08-13.23-17.33-7.01-9.38-7.38-7.51
EPS (Recurring)-0.23-0.23-0.23-0.33-0.19-0.26-0.21-0.21
EPS (Basic, Before Extraordinaries)-0.23-0.23-0.23-0.33-0.19-0.26-0.21-0.21
EPS (Diluted)-0.23-0.23-0.23-0.33-0.19-0.26-0.21-0.21
EBITDA-15.98-17.97-15.87-16.09-6.82-8.21-7.08-7.43
Non-Operating Income (Expense)0.913.643.32-0.550.51-0.480.360.31
Other After Tax Adjustments0.000.000.020.000.000.000.000.00
Stock Option Compensation Expense1.832.401.784.190.330.880.890.35
Shares Outstanding67.2465.4761.8151.9450.6035.9635.8535.64
Market Capitalization513.06431.81445.28382.39212.16206.49117.59112.92

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments80.5633.1019.3418.2623.670.120.890.603.18
Short Term Receivables0.670.230.190.090.340.491.041.091.05
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets3.861.110.270.240.210.290.100.120.10
Total Current Assets85.1034.4419.8018.5924.230.892.031.814.33
Net Property, Plant & Equipment0.990.420.460.530.470.250.500.320.33
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.000.000.000.00
Other Assets0.060.080.010.000.020.000.000.000.00
Total Assets86.1534.9420.2719.1224.721.142.532.134.66
Short Term Debt Incl. Current Port. of LT Debt0.080.0710.450.130.1213.5812.167.670.01
Accounts Payable0.000.000.000.000.000.000.000.000.00
Income Tax Payable0.000.000.040.00-----
Other Current Liabilities5.553.038.892.931.674.123.772.830.58
Total Current Liabilities5.633.1019.373.061.8017.6915.9410.500.58
Long Term Debt0.080.000.008.867.440.160.190.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.300.380.000.00
Total Liabilities5.703.1019.3711.919.2418.1516.5210.500.59
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value29.7431.710.000.000.000.000.000.000.00
Common Equity52.301.702.227.7916.14-16.65-13.64-8.104.77
Total Shareholders Equity82.0433.402.227.7916.14-16.65-13.64-8.104.77
Accumulated Minority Interest-1.60-1.57-1.32-0.58-0.66-0.36-0.34-0.28-0.70
Total Equity80.4531.840.897.2115.48-17.00-13.98-8.374.08
Total Liabilities & Stockholders Equity86.1534.9420.2719.1224.721.142.532.134.66
Book Value Per Share1.010.050.080.361.13-1.29-1.06-0.630.37
Tangible Book Value Per Share1.010.050.080.361.13-1.29-1.06-0.630.37
Full-Time Employees4933292123-12--
Price to Book Ratio4.9111.8617.613.892.031.76---
Return on Assets-63.71-92.39-143.39-96.69-141.82-162.21-231.94-300.57-
Return on Equity-66.83-143.19-482.25-237.46-----
Return on Invested Capital-46.98-76.34-1,273.38-111.10-77.76----69.66
Quick Ratio15.1211.101.026.0813.490.050.130.177.42
Current Ratio15.1211.101.026.0813.490.050.130.177.42

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-58.42-38.61-25.74-28.97-18.99-18.64-2.99-5.46-11.44
Depreciation0.480.240.170.160.150.090.090.150.10
Other Funds (Non Cash)8.9410.532.342.782.937.041.441.044.08
Funds from Operations-49.00-27.84-23.23-26.04-15.91-11.51-1.46-4.26-7.27
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital5.30-0.71-6.765.351.51-0.171.160.360.85
Cash from Operating Activities-43.71-28.55-29.99-20.68-14.40-11.68-0.30-3.90-6.42
Capital Expenditures-0.82-0.59-0.10-0.07-0.24-0.340.00-0.01-0.11
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.030.000.000.000.060.000.00
Purchase or Sale of Investments-49.140.000.000.0010.07-7.180.000.000.00
Purchase of Investments-78.890.000.000.00-3.27-7.180.000.000.00
Sale Or Maturity of Investments29.760.000.000.0013.340.000.000.000.00
Other Uses0.000.000.000.000.00-4.04-0.04-1.420.00
Other Sources0.000.000.000.000.000.040.000.000.00
Cash from Investing Activities-49.95-0.59-0.08-0.079.83-11.530.02-1.43-0.11
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock79.9276.0654.9221.1610.9430.180.000.001.28
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock79.9276.0654.9221.1610.9430.180.000.001.28
Proceedsfrom Stock Options57.0673.8954.5615.8910.6430.180.000.001.28
Issuance or Reduction of Debt, Net0.000.00-9.14-0.08-0.079.71-0.395.662.81
Change in Long Term Debt0.000.00-0.06-0.08-0.070.000.000.00-0.01
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.00-0.06-0.08-0.070.000.000.00-0.01
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities79.9276.0645.7821.0110.8039.81-0.475.584.09
Exchange Rate Effect-0.740.54-1.960.82-0.51-0.07---
Net Change in Cash-14.4847.4613.761.085.7316.54-0.750.25-2.44
Free Cash Flow-44.53-29.14-30.10-20.76-14.63-12.02-0.30-3.90-6.53
Preferred Dividends (Cash Flow)---0.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments126.42133.66138.8880.5688.9619.77
Short Term Receivables0.200.690.660.670.140.13
Inventories0.000.000.000.000.000.00
Other Current Assets3.332.462.583.862.302.93
Total Current Assets129.95136.80142.1385.1091.4022.83
Net Property, Plant & Equipment4.563.053.170.990.850.69
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.00
Other Assets0.050.050.060.060.100.08
Total Assets134.56139.91145.3586.1592.3523.60
Short Term Debt Incl. Current Port. of LT Debt0.510.160.200.080.080.04
Accounts Payable0.000.000.000.000.000.00
Income Tax Payable0.010.020.020.00--
Other Current Liabilities10.088.377.145.553.732.58
Total Current Liabilities10.618.557.365.633.812.62
Long Term Debt2.911.681.800.080.090.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities13.5210.239.175.703.912.62
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value29.5229.5229.7429.7431.7131.71
Common Equity91.52101.75108.0552.3058.32-9.15
Total Shareholders Equity121.05131.28137.7882.0490.0322.55
Accumulated Minority Interest0.00-1.60-1.60-1.60-1.59-1.58
Total Equity121.05129.67136.1980.4588.4420.98
Total Liabilities & Stockholders Equity134.56139.91145.3586.1592.3523.60
Book Value Per Share1.361.551.751.011.15-0.25
Tangible Book Value Per Share1.361.551.751.011.15-0.25
Full-Time Employees---49--
Price to Book Ratio4.913.787.196.55-23.19-66.57
Return on Assets-52.06-61.39-50.91-63.71-57.20-119.23
Return on Equity-55.97-65.25-53.42-66.83-59.01-154.90
Return on Invested Capital-12.30-10.90-9.05-20.35-7.06-38.75
Quick Ratio12.2516.0019.3015.1223.988.72
Current Ratio12.2516.0019.3015.1223.988.72

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-14.93-14.37-12.65-16.47-6.43-9.02
Depreciation0.180.130.090.070.060.06
Other Funds (Non Cash)2.32-0.11-0.397.120.091.91
Funds from Operations-12.44-14.34-12.95-9.28-6.27-7.05
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital1.361.362.80-0.231.73-1.51
Cash from Operating Activities-11.08-12.99-10.15-9.50-4.54-8.57
Capital Expenditures-0.13-0.17-0.33-0.19-0.06-0.17
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments30.220.37-79.720.000.000.00
Purchase of Investments0.460.37-79.720.000.000.00
Sale Or Maturity of Investments29.760.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities30.090.20-80.05-0.19-0.06-0.17
Cash Dividends Paid0.000.000.000.000.000.00
Change in Capital Stock3.707.1268.580.5275.020.25
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock3.707.1268.580.5275.020.25
Proceedsfrom Stock Options8.89-9.5058.63-0.9775.020.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities3.707.1268.580.5275.020.25
Exchange Rate Effect-0.04-0.28-0.450.03-0.140.56
Net Change in Cash22.68-5.94-22.06-9.1570.28-7.92
Free Cash Flow-11.21-13.16-10.47-9.69-4.60-8.74

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3011.42%6.2M54.7M634.06K
2026-10-1512.12%6.5M54.0M611.45K
2026-09-3012.70%6.8M53.5M439.32K
2026-09-1514.17%7.6M53.5M434.98K
2026-08-3113.29%7.1M53.5M371.57K
2026-08-1411.83%6.3M53.6M360.50K
2026-07-3111.42%6.0M52.9M348.85K
2026-07-1511.19%5.9M52.9M293.90K
2026-06-3010.47%5.5M52.2M279.68K
2026-06-158.81%4.6M52.2M223.57K
2026-05-297.82%4.1M52.2M211.40K
2026-05-157.25%3.6M49.1M218.34K
2026-04-306.23%3.1M49.4M224.84K
2026-04-155.19%2.6M49.5M222.65K
2026-03-315.38%2.5M47.3M227.62K
2026-03-135.29%2.5M47.3M211.43K
2026-02-275.08%2.0M38.9M190.69K
2026-02-134.23%1.7M39.2M161.70K
2026-01-303.80%1.5M38.7M157.58K
2026-01-153.69%1.4M39.1M140.06K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-106-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-10SEC
2026-11-10SUPPLVoluntary supplemental material filed pursuant to Section 11(a) of the Securities Act of 1933 by foreign issuersSEC
2026-11-106-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-10SEC
2026-11-106-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-10SEC
2026-11-106-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-10SEC
2026-10-226-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-22SEC
2026-10-156-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-15SEC
2026-10-096-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-09SEC
2026-09-306-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-30SEC
2026-09-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-08SEC
2026-09-02SUPPLVoluntary supplemental material filed pursuant to Section 11(a) of the Securities Act of 1933 by foreign issuersSEC
2026-08-24EFFECTEffectiveness filing by commission orderSEC
2026-08-19F-10/ASEC
2026-08-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-13SEC
2026-08-13SCHEDULE 13G/ASEC
2026-08-116-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-11SEC
2026-08-06F-XFor appointment of agent for service of process by issuers registering securities (if filed on Form F-8, F-9, F-10 or F-80, or registering securities or filing periodic reports on Form 40-F, or by any person filing certain tender offer documents, or by anSEC
2026-08-06F-10Registration statement for securities of certain Canadian issuers under the Securities Act of 1933SEC
2026-07-156-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-15SEC
2026-07-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-13SEC
2026-07-076-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-07SEC
2026-06-226-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-19SEC
2026-05-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-18SEC
2026-05-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-28SEC
2026-05-286-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-28SEC
2026-05-126-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-12SEC
2026-05-12SCHEDULE 13G/ASEC
2026-05-066-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-06SEC
2026-05-056-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-05SEC
2026-05-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-01SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Beutel, Goodman & Co Ltd.5.35%
Affinity Asset Advisors, LLC2.53%
SCOTIA CAPITAL INC.2.16%
BALYASNY ASSET MANAGEMENT L.P.2.07%
Vivo Capital, LLC2.07%
PFM Health Sciences, LP1.85%
GREAT POINT PARTNERS LLC1.84%
Jupiter Topco LLC1.60%
Rubric Capital Management LP1.33%
Ikarian Capital, LLC1.24%

Funds

Fund% owned
Fidelity Nasdaq Composite Index Fund0.06%
Blackstone Alternative Multi-Strategy Fund0.00%

OakChart. EPRX. Cached 15 minutes.

Some panels did not load: insider.